Benchmark Holdings Plc Logo

Benchmark Holdings Plc

Aquaculture biotech providing nutrition and health solutions for sustainable farming.

BMK | IL

Overview

Corporate Details

ISIN(s):
GB00BGHPT808 (+1 more)
LEI:
2138001UQHM4VZGXUJ19
Country:
United Kingdom
Address:
4 PARK SQUARE, THORNCLIFFE PARK, CHAPELTOWN, S35 2PH SHEFFIELD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Benchmark Holdings plc is a leading aquaculture biotechnology company dedicated to driving sustainability in the industry. The company's mission is to provide aquaculture producers with mission-critical products and solutions that enhance farming efficiency, animal health, and welfare. Benchmark's operations are centered around two key divisions: Advanced Nutrition and Health. Its portfolio includes specialized diets, probiotics, vaccines, medicines, and other health products designed to improve productivity and sustainability for its global customer base. By combining biology and technology, Benchmark supports the growth of a sustainable food supply chain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-18 08:00
Delisting Announcement
Cancellation of Admissions to Trading
English 11.1 KB
2025-08-15 08:00
Delisting Announcement
Last day of trading
English 6.0 KB
2025-08-15 08:00
Delisting Announcement
Benchmark Holdings plc – Last day of trading
English 1.1 KB
2025-08-08 14:06
Delisting Announcement
Update on the cancellation of trading of shares
English 16.2 KB
2025-08-08 14:00
Delisting Announcement
Update on Euronext Oslo Børs approval of the cancellation of the trading of Ben…
English 4.1 KB
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Decision on date of delisting
English 749 bytes
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Vedtak om dato for strykning
Norwegian 766 bytes
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 16.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights - Attachment: BMK RNS TVR 31 July.pdf
English 82.3 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 361 bytes
2025-07-25 18:37
Delisting Announcement
Result of Tender Offer - Replacement
English 23.9 KB
2025-07-25 18:30
Declaration of Voting Results & Voting Rights Announcements
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interest…
English 77.2 KB
2025-07-25 18:30
M&A Activity
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interests
English 1.1 KB
2025-07-25 08:00
Share Issue/Capital Change
Result of Tender Offer, Total Voting Rights and Directors' Interests - Attachm…
English 68.6 KB
2025-07-25 08:00
Declaration of Voting Results & Voting Rights Announcements
Result of Tender Offer, Total Voting Rights and Directors' Interests
English 842 bytes

Automate Your Workflow. Get a real-time feed of all Benchmark Holdings Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Benchmark Holdings Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Benchmark Holdings Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.